In a groundbreaking study, scientists have unlocked a key piece of the obesity puzzle, discovering that a naturally occurring hormone can reverse weight gain by targeting the same control center in the brain as popular weight-loss drugs such as Ozempic and Wegovy.
The study, led by researchers at the University of Oklahoma and published in Cell reportshighlighted the hormone FGF21 as a powerful tool in regulating metabolism and appetite.
For years, scientists assumed that weight-regulating signals were primarily directed to the hypothalamus. Dr. However, Matthew Potthoff and his team were surprised to find that FGF21 actually bypasses that area and instead sends signals to the hindbrain, the lower back part of the brain.
“We were very surprised to find that the signal went to the hindbrain,” says Dr. Potthoff.
FGF21 interacts with two specific parts of the hindbrain, which then send a message to the parabrachial nucleus. This chain reaction effectively reduces appetite and stimulates metabolism, leading to significant weight reversal in mice.
It is striking that FGF21 is already being used at an accelerated pace in clinical trials for the treatment of fatty liver disease (MASH); these new findings suggest its potential is much broader.
By understanding exactly how this hormone mimics the success of GLP-1 drugs, researchers hope to develop new and more targeted therapies for obesity that could offer fewer side effects or better long-term results than current treatments.
“This brain circuit appears to mediate the effects of FGF21,” Potthoff said. “We hope that by identifying the specific circuit it can help create more targeted therapies that are effective without negative side effects. FGF21 analogs have side effects such as gastrointestinal problems and, in some cases, bone loss.”
“Although this study focused on the mechanism of FGF21 to reduce body weight, additional studies are needed to investigate whether this circuit also mediates the ability of FGF21 and FGF21 analogs to reverse MASH,” he added.
